Lilly Spikes Post Alzheimer's Flop On Street-Topping 2017 Guidance

Eli Lilly (LLY) stock popped to a three-week high Thursday — its highest point since terminating a key Alzheimer's program in November — on its Wall Street-topping 2017 sales and earnings guidance.

Early Thursday, Lilly guided to $21.8 billion to $22.3 billion in 2017 sales, topping the consensus of 21 analysts polled by Thomson Reuters for $21.67 billion. Lilly also sees $4.05 to $4.15 earnings per share ex items, beating analysts' model for $3.97.

"This is the first time Lilly has...

What feeling does this article give you?

#hashtags to follow:

Eli Lilly [+]    LLY [+]    Alzheimer [+]    Wall Street [+]    Early Thursday [+]    Lilly [+]    Thomson Reuters [+]   

More #news: